TMB Substrate Set

Pricing & Availability
Regulatory Status
RUO
Other Names
TMB Substrate
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Save
421101 110 ml x 2 ¥8,190
Description

The TMB Substrate Set contains 110 ml TMB Substrate A and 110 ml TMB Substrate B, sufficient for twenty 96-well plates. It is formulated with 3, 3', 5, 5' tetramethyl benzidine (TMB). The substrate can be catalyzed with peroxidase to produce a pale blue color which can be read spectrophotometrically at 370 or 620-650 nm. The TMB reaction may be stopped with BioLegend's Stop Solution (Cat. No. 423001), and read at 450 nm.

Product Details
Technical data sheet

Product Details

Storage & Handling
The TMB Substrate Set (TMB Substrate A and TMB Substrate B) should be stored between 2°C and 8°C. Avoid prolonged exposure to light, contact with metal, air, or extreme temperatures.
Application

ELISA

Recommended Usage

TMB Substrate A should be clear and colorless.
TMB Substrate B should be colorless to a very light amber.
TMB Substrate is the mixture of equal volumes of TMB Substrate A with TMB Substrate B. For example, for one plate, mix 5.5 ml TMB Substrate A with 5.5 ml of TMB Substrate B in a clean container. Mix immediately before use.
After mixing the reagents together, TMB substrate working solution should be colorless or very faint blue.

Application Notes

Warm to room temperature prior to use. To prepare a working solution, mix equal volumes of TMB Substrate A and TMB Substrate B. Prepare only the amount needed for each assay run. After wells are completely washed, to remove unbound antibody and HRP, add 100 µl to 200 µl substrate solution to each well. Discard any remaining working solution after use. For endpoint assays, add 50 µl to 100 µl of Stop Solution (2N H2SO4 or 1M H3PO4), which changes the color from blue to yellow. Read at 450 nm (minus 570 nm for wavelength correction) within 30 minutes of stopping the reaction. For kinetic assays, read the blue color at 620 - 650 nm.

Application References

(PubMed link indicates BioLegend citation)
  1. Kim MS, et al. 2008. J Biochem. 143:497. PubMed
  2. McNally A, et al. 2011. PNAS. 108:7529. PubMed
  3. Santiago FW, et al. 2012. Vaccine. 30:4606. PubMed
  4. Wan LY, et al. 2014. Toxicol Sci. PubMed
  5. de Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed
Product Citations
  1. Wenzek C, et al. 2022. iScience. 25:105540. PubMed
  2. Bryant JD, et al. 2021. Brain Behav Immun. 97:204. PubMed
  3. Jameie F, et al. 2020. Arch Razi Inst. 75:327. PubMed
  4. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  5. Jameie F, et al. 2021. Iran J Parasitol. 1:16. PubMed
  6. Hsiue EH, et al. 2021. Science. 371:. PubMed
  7. Peng L, et al. 2022. Cell Rep. 40:111160. PubMed
  8. Liu W, et al. 2016. J Virol. 90: 8496 - 8508. PubMed
  9. Fertey J, et al. 2021. Methods Mol Biol. 2414:97. PubMed
  10. He Y, et al. 2021. Bio Protoc. 11:e3905. PubMed
  11. Brooks JF, et al. 2020. J Immunol. 205:1239. PubMed
  12. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  13. Lee JL, et al. 2022. Aging Cell. 21:e13692. PubMed
  14. Alapati T, et al. 2021. Genes (Basel). 13:. PubMed
  15. Chang JH, et al. 2022. Vaccines (Basel). 10:. PubMed
  16. Sari AN, et al. 2022. Cancers (Basel). 14:. PubMed
  17. Stebegg M, et al. 2019. Nat Commun. 2.113194444. PubMed
  18. Sen K, et al. 2021. Front Immunol. 12:733539. PubMed
  19. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  20. Ding P, et al. 2022. Cell Rep. 39:110851. PubMed
  21. Walczewska M, et al. 2017. Adv Exp Med Biol. 10.1007/978-94-024-1079-2_41. PubMed
  22. Ramos-Pinto L, et al. 2021. Animals (Basel). 11:. PubMed
  23. Wu J, et al. 2020. Immunity. 53:115. PubMed
  24. Malik V, et al. 2020. Int J Mol Sci. 21:00. PubMed
  25. Oh E, et al. 2018. Front Oncol. 0.716666667. PubMed
  26. Schwaderer J, et al. 2020. Cell Death Dis. 11:154. PubMed
  27. Nuvolone M, et al. 2017. PLoS One. 12:e0171923. PubMed
  28. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  29. Debernardi S, et al. 2020. PLoS Med. 17:e1003489. PubMed
  30. Morgan S, et al. 2016. J Immunol. 196: 5014 - 5023. PubMed
  31. Fang Z, et al. 2022. Nat Commun. 13:3250. PubMed
  32. Younis RH, et al. 2021. Front Immunol. 596646:12. PubMed
  33. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  34. Sun L, et al. 2021. Sci Rep. 11:12477. PubMed
  35. Wu J, et al. 2021. Nat Cell Biol. 23:75. PubMed
  36. Pagan JD, et al. 2018. Cell. 172:564. PubMed
  37. Del Alcazar D, et al. 2019. Cell Rep. 28:3047. PubMed
  38. Groeneveld D, et al. 2020. J Hepatol. 72:146. PubMed
  39. Nogales A, et al. 2017. Virology. 500:1-10. PubMed
  40. Wan L, et al. 2014. Toxicol Sci. 139:83. PubMed
  41. Falck-Jones S, et al. 2021. J Clin Invest. 131: . PubMed
  42. Vijver SV, et al. 2021. Front Immunol. 12:733561. PubMed
  43. Barbier M, et al. 2022. Front Immunol. 13:948431. PubMed
  44. Garg S, et al. 2019. Biotechniques. 67:166. PubMed
  45. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  46. Yang K, et al. 2020. Cell Chem Biol. 27:866. PubMed
  47. McNally A, et al. 2011. Proc Natl Acad Sci U S A. 108:7529. PubMed
  48. Surawut S, et al. 2017. Sci Rep. 7:40006. PubMed
  49. Strazza M, et al. 2022. Mol Ther Methods Clin Dev. 27:380. PubMed
  50. Pedicone C, et al. 2022. iScience. 25:104170. PubMed
  51. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  52. Kim M, et al. 2008. J Biochem. 143:497. PubMed
  53. Miller H, et al. 2021. J Clin Microbiol. 59:e0096421. PubMed
  54. Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed
  55. Guo Y, et al. 2021. Nat Commun. 12:2623. PubMed
  56. Leppkes M, et al. 2020. EBioMedicine. 58:102925. PubMed
  57. Parrish H, et al. 2016. Proc Natl Acad Sci U S A. 113: 3000 - 3005. PubMed
  58. Pablo P, et al. 2014. Ann Rheum Dis. 73:580. PubMed
  59. Reis B, et al. 2021. Mar Drugs. 19:. PubMed
  60. Knopf J, et al. 2022. Cells. 11:. PubMed
  61. Lee KS, et al. 2022. iScience. 25:105038. PubMed
  62. Yang K, et al. 2021. STAR Protoc. 2:100288. PubMed
  63. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  64. Santiago F, et al. 2012. Vaccine. 30:4606. PubMed

Antigen Details

Gene ID
NA

Related FAQs

What is the difference between your two substrate solutions: TMB Substrate Reagent Set (Cat. No. 421101) and TMB High Sensitivity Substrate Solution (Cat. No. 421501)?

TMB Substrate Reagent Set (Cat. No. 421101) contains two components, which need to be mixed immediately prior to use. The TMB High Sensitivity Substrate Solution (Cat. No. 421501) contains everything in one solution with special stabilizers. It is a high kinetic substrate solution which generally gives higher signal. The type of substrate used for an assay can affect the optical density (OD) achievable and the time required to achieve the desired OD.

Go To Top Version: 4    Revision Date: 05/30/2017

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account